Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1642P - Improve the conditions of lockdown may decrease anxiety among cancer patients during the COVID-19 pandemic

Date

16 Sep 2021

Session

ePoster Display

Topics

COVID-19 and Cancer

Tumour Site

Presenters

Gwenaëlle Gravis Mescam

Citation

Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713

Authors

G. Gravis Mescam1, R. Touzani2, J. Pakradouni3, P. Bens Soussan4, P. Marino5

Author affiliations

  • 1 Medical Oncology Dept., IPC - Institut Paoli-Calmettes, 13273 - Marseille, Cedex/FR
  • 2 Inserm, Ird, Sesstim, Sciences Economiques & Sociales De La Santé & Traitement De L’information Médicale, Equipe Canbios Labellisée Ligue Contre Le Cancer, Aix Marseille Univ, IPC - Institut Paoli-Calmettes, 13009 - Marseille/FR
  • 3 Clinical Research, IPC - Institut Paoli-Calmettes, Marseille/FR
  • 4 Psychology, IPC - Institut Paoli-Calmettes, Marseille/FR
  • 5 Sesstim Umr1252, Institut Paoli-Calmettes, 13009 - Marseille/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1642P

Background

The COVID-19 pandemic is a highly traumatic event that may lead to a greater risk of developing psychological disorders, especially in cancer patients who are more likely to be infected with the virus and to develop complications. The objective of this study was to measure anxiety levels among cancer patient during COVID-19 pandemic and the associated factors including patients’ conditions of lockdown.

Methods

A cross-sectional study was conducted among adult cancer patients (hematological and solid tumors) receiving outpatient treatment or during follow-up in a French Comprehensive Cancer Centre. A postal self-administered questionnaire was sent to 4000 patients in June 2020, including Anxiety (Stait Trait), Fear of a cancer recurrence (FCR) as well as questions relative to socio-demographics, management of cancer care during the pandemic and the conditions of lockdown.

Results

A total of 1097 patients completed the questionnaire (63.2% female; mean age 64.7 years ±12.3 years, 24.3% haematological cancers). Mean IES-R score was 15.7 ([0-81]) and 14.7% of patients had moderate or severe post-traumatic stress (score ≥33). Mean anxiety score was 39.0 (SD=13.6, range: [20-80]) with 30.5% of patients having anxiety symptoms. In the multivariate analysis we found that anxiety level was significantly increased for younger patients (OR=1.69, 95%IC [1.01-2.82]), female (OR=1.65, 95%IC [1.05-2.59]), patients with a high FCR score (OR=4.90, 95%IC [2.84-8.44]), patients unsatisfied with the current management of their cancer (OR=2.4, 95%IC [1.58-3.66]) and patients afraid of coming to hospital for fear of COVID (OR=2.10, 95%IC [1.32-3.35]). Protective factors against anxiety were staying busy during the lockdown period (OR=0.46, 95%IC [0.30-0.72]) and seeing the positive aspects of lockdown (OR=0.43, 95%IC [0.28-0.66]).

Conclusions

These results contribute to a better understanding of the psychological consequences of COVID-19 pandemic in the context of cancer and highlight the need to better support patients at high risk of developing high anxiety levels. Conditions of lockdown are important to contain anxiety among cancer patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Institut Paoli-Calmettes Marseille France.

Funding

Janssen.

Disclosure

G. Gravis Mescam: Financial Interests, Institutional, Advisory Board: BMS; Financial Interests, Institutional, Invited Speaker: Janssen; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Invited Speaker: Astellas; Financial Interests, Institutional, Invited Speaker: MSD; Financial Interests, Institutional, Invited Speaker: Astellas; Financial Interests, Institutional, Invited Speaker: Janssen; Financial Interests, Institutional, Advisory Board: Alliance Merck-Pfizer; Financial Interests, Institutional, Advisory Board: AAA; Financial Interests, Institutional, Invited Speaker: Astellas; Financial Interests, Institutional, Invited Speaker: Janssen; Financial Interests, Institutional, Invited Speaker: AMGEN; Financial Interests, Institutional, Invited Speaker: BMS; Financial Interests, Institutional, Advisory Board: Janssen; Financial Interests, Institutional, Invited Speaker: Sanofi; Financial Interests, Institutional, Funding: Janssen; Financial Interests, Institutional, Invited Speaker: BMS; Non-Financial Interests, Principal Investigator: Ipsen; Non-Financial Interests, Principal Investigator: BMS; Non-Financial Interests, Principal Investigator: Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.